Mark Amenante

Founder and Director of Vlocity.

Prior to Vlocity, Mr. Armenante was Founder and Director at Veeva Systems and led them to a very successful IPO. Prior to Veeva, he served as Vice President of Sales and Group Vice President at Siebel Systems, Inc. He was Siebel’s first VP of Sales, and during his first two years with the company, he developed its revenue from zero to $60 million. In his later years at Siebel, Mr. Armenante and his team grew the company’s sales to $1.6 billion. Mark Armenante also presided over several product launches for Siebel before retiring from the company in 2004.

Mr. Armenante came to Siebel after spending four years building his first company, PharmaSystems, Inc. PharmaSystems, which he founded and served as CEO, pioneered a sales force automation solution targeted at pharmaceutical companies. The business developed a large market share, and in 1994, it was purchased by one of the American Express Company’s units. Mark received a Bachelor of Science from Case Western Reserve University and a MBA from Ohio University.Prior to opening Veeva Systems and Vestry Wines, Mark Armenante spent several decades in executive sales positions.

Young A. Sohn

Founder and Director of Vlocity, Inc.

Prior to Vlocity, Ms. Sohn served as a Director at Veeva Systems Inc. from January 2007 to July 2014. Ms. Sohn led the Siebel Life Sciences Division from November 1997 to December 2001. Ms. Sohn was the Founder of Nomadic Systems, Inc and served as Chief Executive Officer from April 1994 to November 1997. Prior to her time at Nomadic Systems, Ms. Sohn held an executive management position at PharmaSystems. Previously, Ms. Sohn spent six years at Oracle Corporation in the pharmaceutical vertical organization. Ms. Sohn received a Bachelor of Arts degree in Business Management from Cornell University.

Robert Erwin

Chairman, Oryn Therapeutics
President, iBio, Inc., Chairman, Novici Biotech

Mr. Erwin is a veteran of the biotechnology sector. He was chief executive officer of Large Scale Biology Corporation from 1992 to 2003 and served as its chairman until 2006. He was chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. From 2003 until 2007 he was managing director of Bio-Strategic Directors LLC, a life science-industry consulting firm focused on intellectual property and strategy. He is a member of the National Cancer Policy Forum of the Institute of Medicine and a past member of the Research Committee of the American Society of Clinical Oncology and the Data and Safety Monitoring Board of the Cancer and Leukemia Group B. He is currently president of iBio, Inc., a public biotechnology company in Newark, Delaware, and chairman of Novici Biotech LLC in Vacaville, California. He is also managing member of Biospecimen Technologies LLC and serves on the boards of the Marti Nelson Cancer Foundation and the Colorectal Cancer Coalition. He is an inventor on several issued and pending patents.

Richard Selsted

Chief Operating Officer, Oryn Therapeutics

Mr. Selsted joined Oryn’s Executive Team in September 2014. He is responsible for Operations, Marketing, and Corporate Development. Prior to joining Oryn, Mr. Selsted ran the largest Cloud business unit at SAP, the world’s largest software applications company. Mr. Selsted’s business unit covered 13 countries and over 3500 clients. Prior to Mr. Selsted’s career at SAP, he held various executive positions at Oracle Corporation, Siebel Systems, and Solidus Networks. Mr. Selsted holds a bachelor’s degree in environmental sciences from the University of California, Berkeley.